



THE PREVALENCE OF PLASMID MEDIATED AMP^C B-LACTAMASE PRODUCTION IN ENTEROBACTERIACEAE LACKING CHROMOSOMAL AMP^C B-LACTAMASES AT JLN MEDICAL COLLEGE AND ASSOCIATED GROUP OF HOSPITALS, AJMER, RAJASTHAN .

Microbiology

Dr Surbhi Mathur

Assistant professor, Department of Microbiology, JLN medical college, Ajmer, Rajasthan Pin- 305001, India

ABSTRACT

Background: *Enterobacteriaceae* produces Amp^C β-lactamases that make them resistant to commonly used antibiotics. Amp^C β-lactamases can be chromosomal-mediated or plasmid-mediated Amp^C β-lactamases (PABLs). The present study was undertaken to determine the occurrence of PABLs production in clinical isolates in *Klebsiella* and *proteus* species.

Objective: To determine the prevalence of plasmid mediated Amp^C β-lactamase production in Enterobacteriaceae lacking chromosomal Amp^C β-lactamases.

Methodology: In this prospective study all non-duplicate Enterobacteriaceae 100 isolates recovered from various clinical samples submitted in microbiology laboratory of our hospital. Isolated over a period of 3 months were screened for Amp^C β-lactamase production.

Results: Among the 100 clinical isolates tested only 21 isolates were found to harbour Amp^C enzymes Confirmed by Amp^C disk test and cloxacillin inhibitor based method.

Of these isolates, 15 isolates were identified as *Klebsiella* spp. and 6 isolates were identified as *Proteus mirabilis*.

Conclusion: Some of the Amp^C isolates were sensitive to ceftazidime but were either resistant to cefotaxime or ceftazidime or were resistant to both antibiotics. These data indicate that although methods that use ceftazidime in standardised methods to detect Amp^C-harbouring isolates, are useful, they are not perfect. The results in the present study showed that screening should include all the clinical isolates showing resistance to any of the cephalosporins irrespective of their ceftazidime susceptibility status.

KEYWORDS

Enterobacteriaceae, Amp^C B-lactamases

INTRODUCTION

Amp^C enzyme is a β-lactamase that can hydrolyse cephamycins as well as other extended spectrum Cephalosporins and not inhibited by clavulanic acid. Although plasmid mediated Amp^C β-lactamases^[1] were first reported in the late 1980s, many infectious disease personnel remain unaware of their clinical importance. This study detected plasmid mediated Amp^C β-lactamases in organisms lacking chromosomally mediated Amp^C β-lactamase that results in multiple antibiotic resistance leaving few therapeutic options and have been associated with false in vitro susceptibility to cephalosporins.^[2] There is a paucity of data about the prevalence and clinical significance of plasmid mediated Amp^C β-lactamases because many laboratories do not test for this resistance mechanism and current tests are inconvenient, subjective, lack sensitivity and/or specificity, or require reagents that are not readily available. A simple disc based protocol using ceftazidime non-susceptibility as a screening tool, followed by the Amp^C disk test as well as cloxacillin inhibitor based method for confirmation were used to detect Amp^C β-lactamase production.^[3,4]

MATERIALS AND METHODS

This study was conducted at Department of Microbiology of JLN Medical College, Ajmer, Rajasthan.

In this prospective study all non-duplicate Enterobacteriaceae 100 isolates recovered from various clinical samples submitted in microbiology laboratory of our hospital.

Isolated over a period of 3 months were screened for Amp^C β-lactamase production.

Screening for Amp^C β-lactamase:

Screening done by using the disc diffusion method as per CLSI recommendations (CLSI, 2015) and ceftazidime (30 μg) non-susceptible isolates were considered to be screen positive isolates.


Further screening was carried out using the method, in which strains sensitive to ceftazidime and resistant to amoxicillin-clavulanic acid (30/10 μg), and either resistant or intermediate resistant to ceftazidime (30 μg) or ceftazidime (30 μg) and are negative for extended spectrum beta lactamase production, were also included.

Phenotypic confirmation tests for detection of Amp^C β-lactamase:

1. The Amp^C disk test, based on filter paper disks impregnated with EDTA, is a highly sensitive, specific, and convenient means of detection of plasmid mediated Amp^C β-lactamases in organisms lacking a chromosomally mediated Amp^C β-lactamase.

The test is based on use of Tris-EDTA to permeabilize a bacterial cell and release β-lactamases into the external environment. Amp^C disks (i.e., filter paper disks containing Tris-EDTA) were prepared in-house by applying 20 μl of a 1:1 mixture of saline and 100× Tris-EDTA to sterile filter paper disks, allowing the disks to dry, and storing them at 2 to 8°C. The surface of a Mueller-Hinton agar plate was inoculated with a lawn of ceftazidime-susceptible *E. coli* ATCC 25922 according to the standard disc diffusion method. Immediately prior to use, Amp^C disks were rehydrated with 20 μl of saline and several colonies of each test organism were applied to a disk. A 30-μg ceftazidime disk was placed on the inoculated surface of the Mueller-Hinton agar. The inoculated Amp^C disk was then placed almost touching the antibiotic disk with the inoculated disk face in contact with the agar surface. The plate was then inverted and incubated overnight at 35°C in ambient air. After incubation, plates were examined for either an indentation or a flattening of the zone of inhibition, indicating enzymatic inactivation of ceftazidime (positive result), or the absence of a distortion, indicating no significant inactivation of ceftazidime (negative result).

FIG. 1.



2. Inhibitor based methods for detection of Amp^C β-lactamase: The standard disc diffusion method was applied using inoculated Mueller-Hinton agar plates and a 30 μg ceftazidime disc, alone or in combination with the test inhibitor, were placed on the surface of the medium and the plates were incubated overnight at 35°C. An increase of 4 mm in presence of cloxacillin (200 μg), in the inhibition zone diameter, was interpreted as an Amp^C producer organism.

RESULT

Among the 100 clinical isolates tested only 21 isolates were found to harbour Amp^C enzymes. Confirmed by Amp^C disk test and cloxacillin inhibitor based method.

Of these isolates, 15 isolates were identified as *Klebsiella* spp. and 6 isolates were identified as *Proteus mirabilis*, respectively.

Table 1: Frequency of cefoxitin resistance among AmpC-positive and negative isolates

Sr No.	Tested organism(n)	AmpC positive isolates(n)		AmpC negative isolates(n)	
		Cefoxitin resistant	Cefoxitin susceptible	Cefoxitin resistant	Cefoxitin Susceptible
1.	K.pneumoniae(n=71)	7	3	5	56
2.	K.oxytoca(n=15)	4	1	4	6
3.	P.mirabilis(n=14)	3	3	0	8

Table2: Phenotypic methods for detection of plasmid-mediated AmpC β-lactamases

S.No.	Tested isolate	AmpC disk test		Inhibitor based method using cloxacillin	
		positive	Negative	positive	Negative
1.	K.pneumoniae	10	0	10	0
2.	K.oxytoca	5	0	5	0
3.	P.mirabilis	6	0	6	0

DISCUSSION

In this study the AmpC disk test provided a simple, convenient, and accurate means of detection of plasmid-mediated AmpC β-lactamases in organisms lacking chromosomal mediated AmpC β-lactamase, i.e., K.pneumoniae, K. Oxytoca, and P.mirabilis. These organisms are chosen for the study because they are convenient indicator organisms for this resistance mechanism in that a positive test can unequivocally indicate the presence of a foreign, or plasmid mediated AmpC β-lactamase. E.coli isolates that produce r plasmid mediated AmpC β-lactamases were not included in this study, because the test does not discriminate between positive results due to upregulated chromosomally mediated AmpC β-lactamases and those due to plasmid mediated AmpC β-lactamases.^[5,6]

AmpC production in cefoxitin susceptible isolates may have a mechanism similar to that of ESBL producing organisms that appear susceptible to ceftazidime by disc diffusion method. Cefoxitin resistance in AmpC non-producers could be due to some other resistance mechanisms; lack of permeation of porins as one of the resistance mechanism has been reported. Thus, the test accurately distinguished between cefoxitin insusceptibility caused by AmpC production and non-β-lactamase mechanisms, such as reduced outer membrane permeability (porin mutations). Distinguishing between these types of mechanisms is a current diagnostic problem for laboratories wanting to detect AmpC β-lactamases.^[7]

Coproduction of ESBLs did not interfere with the detection of the AmpC β-lactamases. Care is required in interpreting the test with isolates exhibiting reduced carbapenem susceptibility, since this may be due to other, currently rare β-lactamases capable of hydrolyzing cefoxitin, e.g., carbapenemases.^[8]

Paul R. Ingram et al (Feb 2011) their study described a simple disc based protocol using cefoxitin non-susceptibility as a screening tool, followed by the Tris-EDTA method for confirmation, detects BlaAmpC activity with 95% sensitivity and 98% specificity.^[9]

In 2002 Philippon, A., G. Arlet, and G.A. Jacoby stated that plasmid mediated class C β-lactamases have been discovered most frequently in isolates of K.pneumoniae and also in other naturally AmpC species such as K. oxytoca, Salmonella, and P.mirabilis.^[10]

In Jan 2009, Tan et al found that for AmpC detection the best sensitivity (95%) and Specificity (95%) were obtained using a combination of cefoxitin and cloxacillin and applying a cutoff of an increase in zone diameter of ≥4mm.^[11]

Given the need for a test for AmpC β-lactamases and the fact that many clinical laboratories are often short staffed and overworked, the AmpC disk test could fill a current gap in diagnostic microbiology. Adoption of this test would make it possible to learn more about the clinical implications of plasmid-mediated AmpC β-lactamases and to contain the spread of organisms possessing this resistance mechanism. The potential benefits would include better patient outcomes in terms of avoiding inappropriate therapy and a reduction in the escalation of antibiotic resistance through better infection control.

CONCLUSION

Some of the AmpC isolates were sensitive to cefoxitin but were either resistant to cefotaxime or ceftazidime or were resistant to both antibiotics. These data indicate that although methods that use cefoxitin in standardised methods to detect AmpC-harboring isolates, are useful, they are not perfect. The results in the present study showed that screening should include all the clinical isolates showing resistance to any of the cephalosporins irrespective of their cefoxitin susceptibility status.

References

- Brenwald, N.P., Jevons, J., Andrews, L., Ang, A.P., Fraise. 2005. Disc methods for detecting AmpC β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae. J. Antimicrob. Chemother. 56:600-601.
- CLSI (2009). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A8. Wayne, PA: Clinical Laboratory Standard Institute.
- CLSI (2015). Performance Standards for antimicrobial susceptibility testing, M100-S20. Wayne, PA: Clinical and Laboratory Standard Institute.
- Jacoby G.A. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161-182.
- Jennifer A. Black, Ellen Smith Moland, Kenneth S. Thomson: AmpC disc test for detection of plasmid mediated AmpC β-lactamases in Enterobacteriaceae lacking chromosomal mediated AmpC β-lactamases; J. Clin. Microbiol. July 2005 vol. 43 no. 7; 3110-3113.
- Koneman E.W., Allen Sephen D et al: Colour Atlas and Text book of diagnostic microbiology published by J.B. hippere Cott. Company. 6th ed, 2006.
- Manchanda, V., and N.P. Singh. 2003. Occurrence and detection of AmpC β-lactamases among Gram negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J. Antimicrob. Chemother. 51:415-418.
- Murray Patrick R. Manual of Clinical Microbiology, 9th ed, 2007.
- Paul R. Ingram, Tim J.J. Inglis, Tessa R. Vanzetti, Barbara A. Henderson, Gerald B. Hamett and Ronan J. Murray: comparison of methods for AmpC β-lactamase detection in Enterobacteriaceae, 2011; Journal of medical microbiology, 60:715-721. microbiol. 23: 120-4.
- Philippon, A., G. Arlet, and G.A. Jacoby. 2002. plasmid determined AmpC type β-lactamases. Antimicrob. Agents Chemother. 46:1-11.
- Tan, T.Y., Ng, L.S., He, J., Koh, T.H. and Hsu, L.Y. (2009). Evaluation of screening methods to detect plasmid mediated AmpC in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Antimicrob. Agents Chemother. 53, 146-149.